Literature DB >> 20437463

Involvement of an influx transporter in the blood-brain barrier transport of naloxone.

Toyofumi Suzuki1, Aya Ohmuro, Mariko Miyata, Takayuki Furuishi, Shinji Hidaka, Fumihiko Kugawa, Toshiro Fukami, Kazuo Tomono.   

Abstract

Naloxone, a potent and specific opioid antagonist, has been shown in previous studies to have an influx clearance across the rat blood-brain barrier (BBB) two times greater than the efflux clearance. The purpose of the present study was to characterize the influx transport of naloxone across the rat BBB using the brain uptake index (BUI) method. The initial uptake rate of [(3)H]naloxone exhibited saturability in a concentration-dependent manner (concentration range 0.5 microM to 15 mM) in the presence of unlabeled naloxone. These results indicate that both passive diffusion and a carrier-mediated transport mechanism are operating. The in vivo kinetic parameters were estimated as follows: the Michaelis constant, K(t), was 2.99+/-0.71 mM; the maximum uptake rate, J(max), was 0.477+/-0.083 micromol/min/g brain; and the nonsaturable first-order rate constant, K(d), was 0.160+/-0.044 ml/min/g brain. The uptake of [(3)H]naloxone by the rat brain increased as the pH of the injected solution was increased from 5.5 to 8.5 and was strongly inhibited by cationic H(1)-antagonists such as pyrilamine and diphenhydramine and cationic drugs such as lidocaine and propranolol. In contrast, the BBB transport of [(3)H]naloxone was not affected by any typical substrates for organic cation transport systems such as tetraethylammonium, ergothioneine or L-carnitine or substrates for organic anion transport systems such as p-aminohippuric acid, benzylpenicillin or pravastatin. The present results suggest that a pH-dependent and saturable influx transport system that is a selective transporter for cationic H(1)-antagonists is involved in the BBB transport of naloxone in the rat. Copyright (c) 2010 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20437463     DOI: 10.1002/bdd.707

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  11 in total

Review 1.  Naloxone dosage for opioid reversal: current evidence and clinical implications.

Authors:  Rachael Rzasa Lynn; J L Galinkin
Journal:  Ther Adv Drug Saf       Date:  2017-12-13

2.  Incorporation of a Biguanide Scaffold Enhances Drug Uptake by Organic Cation Transporters 1 and 2.

Authors:  Obinna N Obianom; Ana L Coutinho; Wei Yang; Hong Yang; Fengtian Xue; Yan Shu
Journal:  Mol Pharm       Date:  2017-07-21       Impact factor: 4.939

Review 3.  Fentanyl: Receptor pharmacology, abuse potential, and implications for treatment.

Authors:  Sandra D Comer; Catherine M Cahill
Journal:  Neurosci Biobehav Rev       Date:  2018-12-05       Impact factor: 8.989

4.  Indirect SPECT Imaging Evaluation for Possible Nose-to-Brain Drug Delivery Using a Compound with Poor Blood-Brain Barrier Permeability in Mice.

Authors:  Asuka Mizutani; Masato Kobayashi; Makoto Ohuchi; Keita Sasaki; Yuka Muranaka; Yusuke Torikai; Shota Fukakusa; Chie Suzuki; Ryuichi Nishii; Shunji Haruta; Yasuhiro Magata; Keiichi Kawai
Journal:  Pharmaceutics       Date:  2022-05-10       Impact factor: 6.525

5.  Coexistence of passive and proton antiporter-mediated processes in nicotine transport at the mouse blood-brain barrier.

Authors:  Salvatore Cisternino; Hélène Chapy; Pascal André; Maria Smirnova; Marcel Debray; Jean-Michel Scherrmann
Journal:  AAPS J       Date:  2012-12-05       Impact factor: 4.009

6.  Involvement of a novel organic cation transporter in verapamil transport across the inner blood-retinal barrier.

Authors:  Yoshiyuki Kubo; Yusuke Kusagawa; Masanori Tachikawa; Shin-Ichi Akanuma; Ken-Ichi Hosoya
Journal:  Pharm Res       Date:  2012-11-22       Impact factor: 4.200

Review 7.  Surface charge, glycocalyx, and blood-brain barrier function.

Authors:  Fruzsina R Walter; Ana R Santa-Maria; Mária Mészáros; Szilvia Veszelka; András Dér; Mária A Deli
Journal:  Tissue Barriers       Date:  2021-05-18

8.  Naloxone inhibits immune cell function by suppressing superoxide production through a direct interaction with gp91phox subunit of NADPH oxidase.

Authors:  Qingshan Wang; Hui Zhou; Huiming Gao; Shih-Heng Chen; Chun-Hsien Chu; Belinda Wilson; Jau-Shyong Hong
Journal:  J Neuroinflammation       Date:  2012-02-16       Impact factor: 8.322

9.  Blood-brain barrier: mechanisms governing permeability and interaction with peripherally acting μ-opioid receptor antagonists.

Authors:  Eugene R Viscusi; Andrew R Viscusi
Journal:  Reg Anesth Pain Med       Date:  2020-07-28       Impact factor: 6.288

10.  Control and sensation of breathing during cycling exercise in hypoxia under naloxone: a randomised controlled crossover trial.

Authors:  Laurent Koglin; Bengt Kayser
Journal:  Extrem Physiol Med       Date:  2013-01-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.